You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 6, 2025

Suppliers and packagers for generic pharmaceutical drug: ACAMPROSATE CALCIUM


✉ Email this page to a colleague

« Back to Dashboard


ACAMPROSATE CALCIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Bionpharma ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 219904 ANDA Bionpharma Inc., 69452-353-25 180 TABLET, DELAYED RELEASE in 1 BOTTLE (69452-353-25) 2025-12-01
Glenmark Pharms Ltd ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 202229 ANDA Major Pharmaceuticals 0904-7213-04 30 BLISTER PACK in 1 CARTON (0904-7213-04) / 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK 2013-07-16
Glenmark Pharms Ltd ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 202229 ANDA American Health Packaging 60687-121-25 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-121-25) / 1 TABLET, DELAYED RELEASE in 1 BLISTER PACK (60687-121-95) 2015-10-27
Glenmark Pharms Ltd ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 202229 ANDA Glenmark Pharmaceuticals Inc., USA 68462-435-11 10 BLISTER PACK in 1 CARTON (68462-435-11) / 10 TABLET, DELAYED RELEASE in 1 BLISTER PACK 2013-07-16
Glenmark Pharms Ltd ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 202229 ANDA Glenmark Pharmaceuticals Inc., USA 68462-435-18 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68462-435-18) 2013-07-16
Mylan ACAMPROSATE CALCIUM acamprosate calcium TABLET, DELAYED RELEASE;ORAL 200142 ANDA Mylan Pharmaceuticals Inc. 0378-6333-80 180 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (0378-6333-80) 2014-09-24
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers for the Pharmaceutical Drug: ACAMPROSATE CALCIUM

Last updated: July 28, 2025


Introduction

Acamprosate calcium is a prescription medication predominantly used to support abstinence in alcohol-dependent patients. Its role in managing alcohol use disorder (AUD) underscores the importance of a reliable, compliant supply chain. This article provides a comprehensive analysis of suppliers manufacturing acamprosate calcium, highlighting global production hubs, key market players, regulatory considerations, and industry trends pertinent to pharmaceutical companies, healthcare providers, and investors.


Manufacturing Overview of Acamprosate Calcium

Acamprosate calcium’s complex chemical synthesis necessitates specialized manufacturing processes, primarily conducted by pharmaceutical companies with expertise in neuropsychiatric medications. It is produced through multi-step chemical synthesis involving the preparation of its active pharmaceutical ingredient (API) and subsequent formulation into a stable, bioavailable dosage form.

Global production centers are concentrated in regions with robust pharmaceutical manufacturing infrastructures, notably Europe, North America, and Asia. The manufacturing process adheres strictly to Good Manufacturing Practices (GMP), ensuring product consistency, safety, and compliance with regulatory standards such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency).


Leading Suppliers and Manufacturers of Acamprosate Calcium

1. Evapharma and NeuroPharm

Evapharma, headquartered in France, is recognized as the original developer and licensor of acamprosate formulations. Their licensed production partners supply the API globally, with Evapharma continuing to be a primary source for authentic, high-quality acamprosate calcium.

2. SUN Pharmaceutical Industries Ltd.

An India-based pharmaceutical giant, SUN Pharma manufactures acamprosate calcium under licensed agreements, serving both domestic and international markets. Their extensive API production facilities produce high-quality formulations that meet stringent international standards, making them a significant supplier, especially across Asian and emerging markets.

3. Mylan N.V. (now part of Viatris)

Viatris, formed by the merger of Mylan and Pfizer’s Upjohn unit, supplies acamprosate calcium through licensed manufacturing chains. Their global presence and adherence to GMP make them a reliable source for pharmaceutical companies seeking competitively priced, quality API.

4. Teva Pharmaceutical Industries Ltd.

Based in Israel, Teva manufactures a broad spectrum of generic pharmaceuticals, including acamprosate calcium. Their advanced global manufacturing infrastructure supports large-volume production aligned with regulatory compliance.

5. Other Regional Producers

Various Chinese and Indian generic pharmaceutical firms have entered the market, producing acamprosate calcium as part of their neurochemical generic portfolio. Although these suppliers may offer competitive pricing, their regulatory compliance, especially in Western markets, varies and warrants due diligence.


Regulatory and Quality Considerations

The procurement of acamprosate calcium requires careful navigation of regulatory approvals and quality standards. Suppliers must adhere to:

  • GMP standards to ensure safety, efficacy, and reproducibility.
  • Regulatory approvals from authorities like the FDA, EMA, and China Food and Drug Administration (CFDA) for exported APIs.
  • Certificate of Analysis (CoA)s confirming chemical purity, potency, and absence of contaminants.

Ensuring the supplier’s adherence to these standards is critical, given the drug’s indication for a vulnerable patient population—individuals undergoing alcohol withdrawal and abstinence therapy.


Industry Trends and Market Dynamics

1. Increasing Global Demand

As alcohol use disorder remains a significant public health challenge worldwide, demand for acamprosate calcium persists, driven by expanded treatment protocols and increased awareness. Notably, markets in Asia-Pacific and Africa are witnessing robust growth, incentivizing expanded supply chains.

2. Biosimilar and Generic Competition

Generic manufacturers increasingly produce acamprosate calcium, pressuring originator formulations’ prices. Consequently, suppliers are motivated to optimize raw material sourcing, production capacity, and distribution logistics.

3. Supply Chain Risks

Global disruptions, including geopolitical tensions, pandemic impacts, and regulatory shifts, pose risks to consistent supply. Diversifying supplier bases and establishing multiple manufacturing partnerships mitigate these risks.

4. Regulatory Harmonization

Efforts to streamline regulatory pathways across regions facilitate faster approval of APIs and formulations, shortening supply timelines and reducing costs.


Supply Chain and Procurement Strategies

Pharmaceutical firms seeking acamprosate calcium suppliers should perform rigorous due diligence, including:

  • Confirming GMP compliance and manufacturing accreditation.
  • Verifying product stability, batch consistency, and regulatory approvals.
  • Assessing supplier capacity to meet demand fluctuations.
  • Negotiating Intellectual Property (IP) considerations and licensing agreements.
  • Implementing audit processes to ensure ongoing compliance.

Establishing strategic partnerships with multiple suppliers, including regional manufacturers, enhances supply security and competitive pricing.


Conclusion

Suppliers of acamprosate calcium operate primarily across Europe, North America, and Asia, dominated by established pharmaceutical conglomerates such as Evapharma, SUN Pharma, Viatris, and Teva. Their capabilities to produce high-quality, GMP-compliant APIs underpin the global availability of this critical medication for alcohol dependence treatment. Navigating regulatory demands, ensuring supply chain resilience, and aligning with industry standards remain paramount for pharmaceutical entities and healthcare providers engaged in sourcing acamprosate calcium effectively.


Key Takeaways

  • Major Suppliers: Evapharma, SUN Pharma, Viatris, and Teva are primary producers of acamprosate calcium, with regional generic manufacturers supplementing supply.
  • Global Manufacturing Hubs: Strong manufacturing infrastructure exists in Europe, India, and Israel, supporting worldwide distribution.
  • Regulatory Compliance: Ensuring GMP adherence and regulatory approvals is critical to secure high-quality APIs.
  • Market Dynamics: Increasing demand, competitive generics markets, and geopolitical risks influence procurement strategies.
  • Strategic Sourcing: Diversification and rigorous supplier assessments minimize manufacturing disruptions and ensure compliance.

FAQs

1. What factors should I consider when selecting a supplier for acamprosate calcium?
Prioritize GMP compliance, regulatory approvals, product quality (purity, stability), manufacturing capacity, and supply chain reliability. Due diligence and ongoing audits are essential for ensuring supplier credibility.

2. Are there regional differences in acamprosate calcium suppliers?
Yes. European, North American, and Asian manufacturers dominate the market, with regional regulations influencing sourcing decisions. Asian suppliers often offer cost advantages but require careful regulatory validation.

3. How does regulatory compliance impact acamprosate calcium procurement?
Regulatory standards ensure product safety and efficacy. Suppliers must hold appropriate certifications (e.g., FDA, EMA GMP certification), and their APIs should have comprehensive Certificates of Analysis (CoA).

4. What are the risks associated with sourcing acamprosate calcium from regional generic manufacturers?
Potential risks include variable product quality, inconsistent GMP adherence, and regulatory status. Proper qualification and audit processes can mitigate these risks.

5. How do geopolitical factors affect the supply chain for acamprosate calcium?
Trade tensions, tariffs, and regional political stability can disrupt manufacturing and distribution. Diversifying suppliers across regions reduces dependency on single sources.


References

  1. [1] European Medicines Agency. Acamprosate Summary of Product Characteristics.
  2. [2] U.S. FDA. Guidelines for Manufacturing and Quality Control of Active Pharmaceutical Ingredients.
  3. [3] PharmTech. Global Market Analysis of Acamprosate and Related Neuropsychiatric Pharmaceuticals.
  4. [4] MarketWatch. Pharmaceutical Raw Material Sourcing Trends.
  5. [5] World Health Organization. Guidelines on Quality Assurance of Pharmaceuticals.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing